Compounds > tnk-651
Page last updated: 2024-12-08

tnk-651

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TNK-651: Reverse Transcriptase Inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by benzyloxymethyl, isopropyl, and benzyl groups, respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446515
CHEMBL ID436546
CHEBI ID45910
MeSH IDM0509691

Synonyms (26)

Synonym
6-benzyl-1-(benzyloxymethyl)-5-isopropyluracil
6-benzyl-1-benzyloxymethyl-5-isopropyl-1h-pyrimidine-2,4-dione
bdbm50050533
175739-42-1
6-benzyl-1-(benzyloxymethyl)-5-isopropyl-pyrimidine-2,4-dione
2,4(1h,3h)-pyrimidinedione, 5-(1-methylethyl)-1-[(phenylmethoxy)methyl]-6-(phenylmethyl)-
tnk-651
tnk 651
6-benzyl-1-benzyloxymethyl-5-isopropyl uracil
1RT2
chebi:45910 ,
CHEMBL436546 ,
6-benzyl-1-(phenylmethoxymethyl)-5-propan-2-ylpyrimidine-2,4-dione
DB08634
6-benzyl-1-[(benzyloxy)methyl]-5-(propan-2-yl)pyrimidine-2,4(1h,3h)-dione
tnk651
5-(1-methylethyl)-1-[(phenylmethoxy)methyl]-6-(phenylmethyl)-2,4(1h,3h)-pyrimidinedione
6-benzyl-1-[(benzyloxy)methyl]-5-(1-methylethyl)uracil
2,4(1h,3h)-pyrimidinedione, 5-(1-methylethyl)-1-((phenylmethoxy)methyl)-6-(phenylmethyl)-
unii-2hru1h9m1i
2hru1h9m1i ,
DTXSID60170016
6-benzyl-1-[(benzyloxy)methyl]-5-(1-methylethyl)pyrimidine-2,4(1h,3h)-dione
6-benzyl-1-(benzyloxymethyl)-5-isopropylpyrimidine-2,4-dione
5-(1-methylethyl)-1-((phenylmethoxy)methyl)-6-(phenylmethyl)-2,4(1h,3h)-pyrimidinedione
Q27097826
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hiv-1 Reverse TranscriptaseHuman immunodeficiency virus 1IC50 (µMol)0.00600.00600.00700.0080AID977608
Chain A, HIV-1 REVERSE TRANSCRIPTASEHuman immunodeficiency virus 1IC50 (µMol)0.00600.00600.00700.0080AID977608
Chain B, HIV-1 REVERSE TRANSCRIPTASEHuman immunodeficiency virus 1IC50 (µMol)0.00600.00600.00700.0080AID977608
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.03400.00011.076810.0000AID198238; AID292558; AID553262; AID666410; AID734270
Integrase Human immunodeficiency virus 1IC50 (µMol)100.00000.00051.544310.0000AID292559
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID292558Inhibition of HIV1 reverse transcriptase2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
AID666412Cytotoxicity against human MT4 cells after 3 days by XTT assay2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID553260Inhibition of HIV integrase 3' processing activity expressed in Escherichia coli2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID248354Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID292559Inhibition of HIV1 integrase expressed in Escherichia coli BL21 (DE3)2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
AID666414Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID292560Antiviral activity against HIV1 NL4-3 in human PBMC2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
AID734267Cytotoxicity against human MT4 cells after 3 days by XTT assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID553265Therapeutic index, ratio of CC50 for human CEM-SS cells to EC50 for HIV1 3B2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID666413Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID734270Inhibition of HIV1 reverse transcriptase after 1 hr by colorimetric assay2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID198238Inhibitory activity against HIV-1 reverse transcriptase1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
AID734262Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for Human immunodeficiency virus 1 A17 infected in human TZM-bl cells2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID553262Inhibition of HIV1 reverse transcriptase2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID1439175Inhibition of HIV reverse transcriptase polymerase activity assessed as reduction in dNTP incorporation using 100 nucleotide DNA/18 nucleotide DNA as template/primer measured after 30 mins2017European journal of medicinal chemistry, Mar-10, Volume: 1286-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase.
AID553264Cytotoxicity in human CEM-SS cells after 6 days by MTS assay2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID734271Cytotoxicity against human TZM-bl cells2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734265Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID666410Inhibition of HIV1 reverse transcriptase using poly(ra)/oligo(dT)15 homopolymer template as substrate after 1 hr2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID734266Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734261Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 A17 infected in human MT4 cells2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID666416Selectivity index, ratio of CC50 for human MT4 cells to EC50 for NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID734263Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 SF33 infected in human MT4 cells2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734264Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for Human immunodeficiency virus 1 SF33 infected in human TZM-bl cells2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734260Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID553263Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by MTS assay2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID1439177Antiviral activity against HIV1 infected in human P4R5 cells assessed as reduction in viral infection preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by fluorescence based beta-galactosidase reporter gene assay2017European journal of medicinal chemistry, Mar-10, Volume: 1286-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase.
AID734256Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID292561Cytotoxicity against human PBMC2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
AID292562Theraputc index, ratio of CC50 of PBMC cells to EC50 of HIV1 NL4-32007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Rationally designed dual inhibitors of HIV reverse transcriptase and integrase.
AID734257Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734258Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID734255Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID666415Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 SF332012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID553261Inhibition of HIV integrase strand transfer activity expressed in Escherichia coli2011ACS medicinal chemistry letters, Jan, Volume: 2, Issue:1
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and Integrase.
AID1439174Inhibition of RNase H activity of full length HIV reverse transcriptase using RNA-DNA duplex HTS-1 substrate2017European journal of medicinal chemistry, Mar-10, Volume: 1286-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase.
AID734259Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1439181Cytotoxicity against human P4R5 cells2017European journal of medicinal chemistry, Mar-10, Volume: 1286-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's4 (40.00)29.6817
2010's5 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		2.4820pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
nsc 615985
NSC 615985: structure given in first source; potent inhibitor of HIV reproduction		2.0210
ag-1549
capravirine: a non-nucleoside reverse transcriptase inhibitor		2.0210
aurintricarboxylic acid
Aurintricarboxylic Acid: A dye which inhibits protein biosynthesis at the initial stages. The ammonium salt (aluminon) is a reagent for the colorimetric estimation of aluminum in water, foods, and tissues.. aurintricarboxylic acid : A member of the class of quinomethanes that is 3-methylidene-6-oxocyclohexa-1,4-diene-1-carboxylic acid in which the methylidene hydrogens are replaced by 4-carboxy-3-hydroxyphenyl groups. The trisodium salt is the biological stain 'chrome violet CG' while the triammonium salt is 'aluminon'.		2.0210monohydroxybenzoic acid;
quinomethanes;
tricarboxylic acid		fluorochrome;
histological dye;
insulin-like growth factor receptor 1 antagonist
loviride
loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase		2.0210
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.7530cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
delavirdine
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.		2.0210aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide		antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.0410azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
efavirenz
efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.		2.0210acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		2.4120aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
emivirine
emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase. emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.		8.1350pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
dpc 961
[no description available]		2.0210
r 86183
[no description available]		2.0210
nsc 629243
NSC 629243: structure given in first source; an anti-HIV drug		2.0210
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.0210
uc-781
[no description available]		2.0210
ly 73497
LY 73497: HIV-1 reverse transcriptase inhibitor; structure in first source		2.0210
raltegravir
[no description available]		2.06101,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide		antiviral drug;
HIV-1 integrase inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		02.1510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.1510